Processa Pharmaceuticals Inc
PCSA0.193USD
-0.014-6.75%
收盘 09/19, 16:00（美东）报价延迟15分钟
7.79M总市值
亏损市盈率 TTM
关于 Processa Pharmaceuticals Inc 公司
Processa Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司。该公司专注于利用其监管科学方法，包括与食品和药物管理局 (FDA) 的 Project Optimus Oncology 计划和相关的 FDA 指导草案相关的原则，开发下一代化疗 (NGC) 肿瘤药物产品。其正在研发的三种 NGC 治疗药物是 NGC-卡培他滨 (NGC-Cap)、PCS3117（也称为 NGC-吉西他滨 (NGC-Gem)）和 PCS11T（也称为 NGC-伊立替康 (NGC-Iri)）。NGC-Cap 是 PCS6422 和卡培他滨的组合，卡培他滨是抗癌药物 5-氟尿嘧啶的口服前体药物。 PCS3117 是吉西他滨的口服类似物，通过与吉西他滨不同的酶系统转化为其活性代谢物，导致吉西他滨患者和一些对吉西他滨治疗有抵抗力的患者产生积极反应。PCS11T 是伊立替康 (SN-38) 活性代谢物的前体药物。
公司简介
公司代码PCSA
公司名称Processa Pharmaceuticals Inc
上市日期Oct 07, 2013
CEOMr. George K. Ng
员工数量10
证券类型Ordinary Share
年结日Oct 07
公司地址601 21St Street, Suite 300
城市VERO BEACH
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编32960
电话14437763133
网址https://www.processapharmaceuticals.com/
公司代码PCSA
上市日期Oct 07, 2013
CEOMr. George K. Ng
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. David Young, Ph.D.
Dr. David Young, Ph.D.
President - Research and Development, Director
President - Research and Development, Director
236.18K
+5.32%
Mr. George K. Ng
Mr. George K. Ng
Chief Executive Officer, Director
Chief Executive Officer, Director
107.20K
-28.91%
Mr. Patrick Lin
Mr. Patrick Lin
Chief Business and Strategy Officer
Chief Business and Strategy Officer
103.98K
+10.25%
Dr. Sian Bigora, Pharm.D.
Dr. Sian Bigora, Pharm.D.
Chief Development Officer and Regulatory Officer, Founder
Chief Development Officer and Regulatory Officer, Founder
33.63K
+53.70%
Ms. Wendy Guy
Ms. Wendy Guy
Founder, Chief Administrative Officer
Founder, Chief Administrative Officer
26.34K
+122.14%
Ms. Geraldine Pannu
Ms. Geraldine Pannu
Independent Director
Independent Director
2.88K
--
Mr. Khoso Baluch
Mr. Khoso Baluch
Independent Director
Independent Director
1.40K
--
Mr. Russell L. Skibsted
Mr. Russell L. Skibsted
Chief Financial Officer
Chief Financial Officer
--
--
Mr. James R. (Jim) Neal
Mr. James R. (Jim) Neal
Independent Director
Independent Director
--
--
Mr. Justin W. Yorke
Mr. Justin W. Yorke
Independent Chairman of the Board
Independent Chairman of the Board
--
--
名称
名称/职务
职务
持股
持股变动
Dr. David Young, Ph.D.
Dr. David Young, Ph.D.
President - Research and Development, Director
President - Research and Development, Director
236.18K
+5.32%
Mr. George K. Ng
Mr. George K. Ng
Chief Executive Officer, Director
Chief Executive Officer, Director
107.20K
-28.91%
Mr. Patrick Lin
Mr. Patrick Lin
Chief Business and Strategy Officer
Chief Business and Strategy Officer
103.98K
+10.25%
Dr. Sian Bigora, Pharm.D.
Dr. Sian Bigora, Pharm.D.
Chief Development Officer and Regulatory Officer, Founder
Chief Development Officer and Regulatory Officer, Founder
33.63K
+53.70%
Ms. Wendy Guy
Ms. Wendy Guy
Founder, Chief Administrative Officer
Founder, Chief Administrative Officer
26.34K
+122.14%
Ms. Geraldine Pannu
Ms. Geraldine Pannu
Independent Director
Independent Director
2.88K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月24日 周日
更新时间: 8月24日 周日
持股股东
股东类型
持股股东
持股股东
占比
HX Entertainment Ltd
10.86%
Young (David)
0.47%
Ng (George K)
0.21%
Virtu Americas LLC
0.21%
Lin (Patrick)
0.21%
其他
88.05%
持股股东
持股股东
占比
HX Entertainment Ltd
10.86%
Young (David)
0.47%
Ng (George K)
0.21%
Virtu Americas LLC
0.21%
Lin (Patrick)
0.21%
其他
88.05%
股东类型
持股股东
占比
Corporation
10.94%
Individual Investor
1.14%
Investment Advisor
0.30%
Research Firm
0.25%
Investment Advisor/Hedge Fund
0.10%
Hedge Fund
0.09%
其他
87.18%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
48
5.43M
20.63%
+4.60M
2025Q1
51
708.86K
10.77%
+202.96K
2024Q4
53
384.33K
11.96%
-82.26K
2024Q3
54
333.95K
11.36%
-132.80K
2024Q2
56
390.99K
14.35%
-120.98K
2024Q1
59
435.26K
19.04%
+41.69K
2023Q4
57
343.21K
27.89%
+52.02K
2023Q3
57
335.15K
27.25%
+38.59K
2023Q2
52
272.47K
22.21%
-24.89K
2023Q1
53
282.76K
23.37%
-80.00
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Young (David)
224.26K
0.86%
-11.93K
-5.05%
May 01, 2025
Ng (George K)
150.80K
0.58%
+43.60K
+40.67%
May 01, 2025
Virtu Americas LLC
43.23K
0.17%
+43.23K
--
Mar 31, 2025
Lin (Patrick)
94.31K
0.36%
+12.08K
+14.69%
May 01, 2025
Yorke (Justin W.)
53.57K
0.2%
+6.20K
+13.09%
May 01, 2025
Geode Capital Management, L.L.C.
34.41K
0.13%
+12.43K
+56.55%
Mar 31, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Jan 18, 2024
Merger
20→1
Jan 18, 2024
Merger
20→1
Jan 18, 2024
Merger
20→1
Jan 18, 2024
Merger
20→1
公告日期
类型
比率
Jan 18, 2024
Merger
20→1
Jan 18, 2024
Merger
20→1
Jan 18, 2024
Merger
20→1
Jan 18, 2024
Merger
20→1
